Logo

scPharmaceuticals Reports Topline Data from the P-I Trial of SCP-111 Autoinjector

Share this
scPharmaceuticals

scPharmaceuticals Reports Topline Data from the P-I Trial of SCP-111 Autoinjector

Shots:

  • The P-I study is assessing the bioavailability, PK/PD, safety & tolerability of furosemide (80mg/mL) SC vs IV (two 40mg) given over 1-to-2 mins., in a difference of 2hrs. among healthy subjects (n=21, 45-80yrs.)
  • The study showed a bioavailability of 107.3%, comparable urine output, urinary sodium & potassium excretion at 6, 8 & 12hrs. and a median pain score of 0 at all evaluated time points. Data will be highlighted at upcoming conferences
  • scPharmaceuticals is expecting sNDA submission to the US FDA during YE’24
Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions